Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
42 hedge funds and large institutions have $10.1M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
2% more funds holding
Funds holding: 41 → 42 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
28% less capital invested
Capital invested by funds: $14.1M → $10.1M (-$3.97M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$122K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$38.4K |
| 3 |
Renaissance Technologies
New York
|
+$18.2K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16.4K |
| 5 |
UBV
United Bank (Virginia)
Vienna,
Virginia
|
+$13.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$209K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$96K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$69.2K |
| 4 |
Jane Street
New York
|
-$59K |
| 5 |
B
Bailard
Foster City,
California
|
-$48.6K |
VIRX Hedge Fund Activity: Q3 2023 in Review
42 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2023, worth a combined $10.1M — down 28% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VIRX positions and 7 closed out — a net gain of 1 holder — while 9 added to existing stakes and 8 trimmed.
The largest buyer was MAI Capital Management, adding an estimated $122K. The largest seller was BlackRock, cutting an estimated $209K.
- 42 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2023, up from 41 in Q2 2023.
- Funds reported $10.1M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2023, down 28% quarter-over-quarter.
- 8 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2023 and 7 closed out, a net change of +1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2023 was MAI Capital Management, an estimated $122K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2023 was BlackRock, an estimated $209K sold.
Based on aggregated 13F filings for Q3 2023.